CA3228509A1 - Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors - Google Patents
Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors Download PDFInfo
- Publication number
- CA3228509A1 CA3228509A1 CA3228509A CA3228509A CA3228509A1 CA 3228509 A1 CA3228509 A1 CA 3228509A1 CA 3228509 A CA3228509 A CA 3228509A CA 3228509 A CA3228509 A CA 3228509A CA 3228509 A1 CA3228509 A1 CA 3228509A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- deuterium
- formula
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163232538P | 2021-08-12 | 2021-08-12 | |
| US63/232,538 | 2021-08-12 | ||
| US202163233059P | 2021-08-13 | 2021-08-13 | |
| US63/233,059 | 2021-08-13 | ||
| PCT/US2022/040190 WO2023018954A1 (en) | 2021-08-12 | 2022-08-12 | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3228509A1 true CA3228509A1 (en) | 2023-02-16 |
Family
ID=83188710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3228509A Pending CA3228509A1 (en) | 2021-08-12 | 2022-08-12 | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240307401A1 (enExample) |
| EP (1) | EP4384173A1 (enExample) |
| JP (1) | JP2024532765A (enExample) |
| AU (1) | AU2022328282A1 (enExample) |
| CA (1) | CA3228509A1 (enExample) |
| WO (1) | WO2023018954A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116870012A (zh) * | 2023-07-26 | 2023-10-13 | 北京大学宁波海洋药物研究院 | 一类甾体硫酸酯化合物在制备jak激酶抑制剂中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9925962D0 (en) | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| PT1390063E (pt) | 2001-05-03 | 2005-03-31 | Hoffmann La Roche | Forma de dosagem farmaceutica de mesilato de nelfinavir amorfo |
| US20060094744A1 (en) | 2004-09-29 | 2006-05-04 | Maryanoff Cynthia A | Pharmaceutical dosage forms of stable amorphous rapamycin like compounds |
| DK3219705T3 (da) | 2005-12-28 | 2020-04-14 | Vertex Pharma | Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid |
| PE20211639A1 (es) | 2009-01-15 | 2021-08-24 | Incyte Holdings Corp | Procesos para preparar inhibidores de jak y compuestos intermediarios relacionado |
| DK3882249T3 (da) | 2012-06-15 | 2025-08-25 | Sun Pharmaceutical Ind Inc | Deutererede derivater af ruxolitinib |
| LT3452039T (lt) | 2016-05-04 | 2024-10-25 | Sun Pharmaceutical Industries, Inc. | Plaukų slinkimo sutrikimo gydymas deuterintais jak inhibitoriais |
| CN107759601B (zh) * | 2016-08-23 | 2020-09-11 | 苏州旺山旺水生物医药有限公司 | 一种jak抑制剂及其盐的制备方法 |
| JP2020520955A (ja) * | 2017-05-23 | 2020-07-16 | セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー | ヤヌスキナーゼ阻害剤のグルクロニドプロドラッグ |
| CN107915738B (zh) | 2017-11-14 | 2019-07-26 | 海化生命(厦门)科技有限公司 | 用于合成巴瑞替尼的关键中间体2的制备方法 |
| CA3129096A1 (en) | 2019-02-06 | 2020-08-13 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| KR20230044411A (ko) | 2020-06-29 | 2023-04-04 | 콘서트 파마슈티컬즈, 인크. | Jak 억제제를 제조하기 위한 방법 및 중간체 |
-
2022
- 2022-08-12 EP EP22764557.9A patent/EP4384173A1/en active Pending
- 2022-08-12 CA CA3228509A patent/CA3228509A1/en active Pending
- 2022-08-12 AU AU2022328282A patent/AU2022328282A1/en active Pending
- 2022-08-12 WO PCT/US2022/040190 patent/WO2023018954A1/en not_active Ceased
- 2022-08-12 JP JP2024508389A patent/JP2024532765A/ja active Pending
- 2022-08-12 US US18/682,339 patent/US20240307401A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4384173A1 (en) | 2024-06-19 |
| AU2022328282A1 (en) | 2024-02-22 |
| JP2024532765A (ja) | 2024-09-10 |
| WO2023018954A1 (en) | 2023-02-16 |
| US20240307401A1 (en) | 2024-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11945816B2 (en) | Inhibitors of EGFR and/or HER2 and methods of use | |
| US11814379B2 (en) | Cyano quinoline amide compounds as HER2 inhibitors and methods of use | |
| US20240083934A1 (en) | N-acetylgalactosamine (galnac)-derived compounds and oligonucleotides | |
| CN104718202B (zh) | 用于制备(s)-3-(4-((4-(吗啉基甲基)苄基)氧基)-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮及其可药用形式的方法 | |
| EP3414224A1 (en) | Inhibitor of indoleamine-2,3-dioxygenase (ido) | |
| CA3149374A1 (en) | Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof | |
| AU2018321548B2 (en) | Processes for preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate | |
| WO2009026444A1 (en) | Ryanodine channel binders and uses thereof | |
| WO2023018954A1 (en) | Treatment of jak-inhibition-responsive disorders with prodrugs of jak inhibitors | |
| US20170029426A1 (en) | Methods and reagents for radiolabeling | |
| WO2021236139A1 (en) | Novel deuterated jak inhibitor and uses thereof | |
| JP2024539922A (ja) | ピリジル含有化合物 | |
| CN112442004A (zh) | 淫羊藿素类似物及其制备方法和应用 | |
| CN118159271A (zh) | 用jak抑制剂的前药治疗jak抑制应答性病症 | |
| CN108472298A (zh) | 选择性激酶抑制剂 | |
| EP3582774A1 (en) | Analogs of vincamine and uses thereof | |
| CN116813646A (zh) | 取代桥环类抑制剂及其制备方法和应用 | |
| EP3421473B1 (en) | Method for preparing pyrrolopyrimidine compounds and application thereof | |
| US20240228475A1 (en) | Processes for the preparation of (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione | |
| WO2025260063A2 (en) | Methods of preparing a prmt5 inhibitor | |
| HK40072576B (zh) | 用作激酶抑制剂的化合物及其应用 | |
| CN116783198A (zh) | 螺环jak抑制剂、含其的药物组合物及其应用 | |
| HK1258226B (en) | Method for preparing pyrrolopyrimidine compounds and application thereof | |
| JPS61200987A (ja) | エブルナモニンオキシム誘導体、その非毒性塩、これらの製法並びにそれを有効成分とする脳機能改善剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240802 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240802 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240802 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250506 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250506 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250507 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250514 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250725 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250725 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250725 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250808 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250808 |